Table 2.
Prevalence of ALT positivity in Human Cancers.
| Tumor | % ALT+ | Range * | Total Tumors Tested, n |
|---|---|---|---|
| Bone | |||
| Chondrosarcoma | 48% | N/A | 31 |
| Ewing Sarcoma | 0% | N/A | 62 |
| Osteosarcoma | 63% | 49–86% | 287 |
| Breast | |||
| Overall | 4% | 2–8% | 552 |
| HER2+ Breast Carcinoma | 18% | 14–21% | 50 |
| Central Nervous System | |||
| Overall | 20% | 10–26% | 4386 |
| Glioma | 30% | 13–69% | 912 |
| NF1 loss-associated glioma | 44% | 29–69% | 167 |
| Astrocytoma (Overall) | 23% | 10–78% | 2231 |
| Diffuse astrocytoma (grade II) | 55% | 27–100% | 95 |
| Anaplastic astrocytoma (grade III) | 65% | 21–92% | 118 |
| Adult glioblastoma (grade IV) | 16% | 11–25% | 862 |
| Pediatric glioblastoma (grade IV) | 39% | 12–56% | 89 |
| Oligodendroglioma | 17% | 0–25% | 78 |
| Oligoastrocytoma | 60% | 11–72% | 48 |
| Ependymoma | 0% | N/A | 260 |
| Medulloblastoma | 7% | 2–22% | 237 |
| Choroid plexus carcinomas | 23% | N/A | 31 |
| Neuroendocrine | |||
| Neuroblastoma | 24% | 18–47% | 843 |
| Pancreatic Neuroendocrine Tumor (PanNET) | 32% | 21–61% | 1152 |
| Soft Tissue | |||
| Angiosarcoma | 23% | 11–24% | 79 |
| Leiomyoma | 3% | 0–3% | 217 |
| Leiomyosarcoma | 60% | 52–78% | 331 |
| Liposarcoma | 27% | 25–29% | 566 |
| Undifferentiated Pleomorphic Sarcoma | 59% | 36–77% | 174 |
*: Minimum and maximum of horizontal range is per the mean ALT+ prevalence acquired of CCA, APB, Telo-FISH (alone), and TRF, respectively (see Table S1). N/A: not applicable – horizontal range could not be generated as this tumor was only assessed via one biomarker.